Table 2.
Univariable and Multivariable Competing Risk Regression for Locoregional Recurrence
| Variable | Univariable Analysis | Multivariable Analysis | ||
|---|---|---|---|---|
| SHR (95% CI) | P | SHR (95% CI) | P | |
| PORT | ||||
| No | 1.00 | 1.00 | — | |
| Yes | 0.46 (0.22, 0.98) | 0.045 | 0.51 (0.22, 1.21) | 0.13 |
| Age at surgery | 1.01 (0.98, 1.04) | 0.6 | ||
| History of smoking | ||||
| No | 1.00 | — | ||
| Yes | 2.62 (0.63, 10.93) | 0.2 | — | — |
| Charlson Comorbidity Index | 1.29 (1.00, 1.66) | 0.05 | 1.30 (0.99, 1.70) | 0.06 |
| Cardiac comorbidity | ||||
| No | 1.00 | — | ||
| Yes | 2.09 (0.96, 4.54) | 0.06 | — | — |
| Pulmonary comorbidity | ||||
| No | 1.00 | — | ||
| Yes | 1.10 (0.49, 2.47) | 0.8 | — | — |
| Preinduction SUVmax primary | 0.99 (0.96, 1.02) | 0.4 | — | — |
| Treatment effect on pathology | ||||
| >90% | 1.00 | — | ||
| <90% | 1.35 (0.16, 11.09) | 0.8 | — | — |
| Pneumonectomy | ||||
| No | 1.00 | — | 1.00 | — |
| Yes | 2.63 (0.42–16.42) | 0.3 | 2.08 (0.26, 16.54) | 0.5 |
| Lymphovascular invasion | ||||
| No | 1.00 | — | ||
| Yes | 0.69 (0.31, 1.52) | 0.4 | — | — |
| Tumor pathologic subtype | ||||
| Squamous, large, other | 1.00 | — | — | |
| Adenocarcinoma | 0.55 (0.21, 1.47) | 0.2 | — | |
| Adjuvant systemic therapy | ||||
| No | 1.00 | — | ||
| Yes | 0.94 (0.34, 2.60) | 0.9 | — | — |
| Pathologic tumor stage (ypT) | ||||
| 1a, 1b, 1c | 1.00 | — | ||
| 2a, 2b | 1.71 (0.75, 3.91) | 0.2 | — | — |
| 3 | 0.99 (0.28, 3.50) | 1.0 | — | — |
| 4 | 1.42 (0.15, 13.83) | 0.8 | — | — |
| 0 | 0.00 (0.00, 0.00) | <0.01 | — | — |
| Multistation ypN2 disease | ||||
| No | 1.00 | — | ||
| Yes | 0.82 (0.33, 2.07) | 0.7 | — | — |
a
Pulmonary comorbidity includes history of tuberculosis, asthma, chronic obstructive pulmonary disease, and/or pulmonary fibrosis, as determined by pulmonary function tests.
b
Major pathologic response.
PORT = postoperative radiotherapy; SHR = subdistribution hazard ratio; SUVmax = maximum standardized uptake value.